# PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

> **NCT00093600** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 69 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** cytarabine
- **DRUG:** daunorubicin hydrochloride
- **DRUG:** midostaurin

## Key facts

- **NCT ID:** NCT00093600
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00093600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00093600, "PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00093600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*